Navigation Links
Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
Date:9/8/2011

In addition, Regulus collaborators Markus Stoffel, Ph.D., M.D. of ETH Zurich will be chairing a session titled "Targeting microRNA," and Thomas Thum, M.D., Ph.D. of Medical School Hannover, Germany will be presenting a talk on "Therapeutic targeting of individual cardiac cell types by microRNA antagonists."

Regulus is advancing multiple microRNA therapeutic programs to the clinic in the areas of fibrosis, immuno-inflammatory disease, metabolic disease, and oncology.

About microRNAs

The discovery of microRNA in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 700 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. A single microRNA can regulate entire networks of genes. As such, these molecules are considered master regulators of the human genome. microRNAs have been shown to play an integral role in numerous biological processes, including the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development. Most microRNAs are conserved across multiple species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways. Indeed, microRNA expression, or function, has been shown to be significantly altered in many disease states, including cancer, heart failure and viral infections. Targeting microRNAs with anti-miRs, antisense oligonucleotide inhibitors of microRNAs, or miR-mimics, double-stranded oligonucleotides to replace microRNA function opens potential for a novel class of therapeutics and offers a unique approach to treating disease by modulating entire biological pathways. To learn more abou
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... February 26, 2015 The ... Bottle washer, Filler, Capper, Blow molder, Shrink wrapper), ... (Still, Flavored, Sparkling) & Region - Trends & ... segments the bottled water processing market with analyses ... terms of value. It also identifies the driving ...
(Date:2/26/2015)... 2015 People with psoriasis and their ... participate in research that aims to improve treatments ... psoriasis registry begins recruiting patients in 2015. ... National Psoriasis Foundation and Corrona, LLC, will initially ... new biologic medication by Novartis Pharmaceuticals for moderate-to-severe ...
(Date:2/26/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company ... announced today that Daniel P. Gold , Ph.D., President ... Company 35 th Annual Health Care Conference on Wednesday, ... Boston Marriott Copley Place. A live webcast of the presentation ... be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Bottled Water Processing Market Worth $2,106.5 Million by 2019 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 4First independent U.S. psoriasis registry will track drug safety and effectiveness 2First independent U.S. psoriasis registry will track drug safety and effectiveness 3MEI Pharma to Present at Cowen and Company Health Care Conference 2MEI Pharma to Present at Cowen and Company Health Care Conference 3
(Date:2/27/2015)... Maryland (PRWEB) February 27, 2015 Dr. James ... shocked by new data saying that 6 people die every ... created a new eBook to address the problem and help ... Update on Alcohol has answers to the following questions:, ... , Do you know what binge drinking is? ...
(Date:2/27/2015)... Aliso Viejo, CA (PRWEB) February 27, 2015 ... of TransFold Volume 3 for Final Cut Pro X. , ... presets built exclusively for FCPX users.” Said Christina ... endless possibilities to any Final Cut Pro X editor.” , ... for Final Cut Pro X. The user can decide to ...
(Date:2/26/2015)... Dallas, Texas (PRWEB) February 27, 2015 ... Industry is a professional and in-depth study on the ... with a focus on the Chinese situation. , ... PEIXING, Enox, SHANGDONG ZOUPING, Hualun, Jiangsu Yuanyang, ZHENGZHOU TONGLI, ... Roma Chemicals and Jain & Jain. , The report ...
(Date:2/26/2015)... 2015 Yisrayl Hawkins, Pastor and Overseer at ... new letter that he says contains absolute proof that the ... starts by showing what the plan, or purpose for mankind ... mankind, which has a beginning and an end. , ... who will believe and walk in His Righteousness, and who ...
(Date:2/26/2015)... Marking its fifth successful year of business, ... announced the development of a new and improved UV-Aid light ... this spring. UV-Aid is a unique and patent pending technology ... in areas of the body susceptible to infection. UVA light ... the daily dose of UV-Aid is equivalent to less than ...
Breaking Medicine News(10 mins):Health News:6 People Die Each Day From Alcohol Poisoning, new Essential Guide to Prescription Drugs eBook seeks to prevent interactions and deaths 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 2Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 3Health News:Yisrayl Hawkins Says There is Only One Place Shown in Scripture to Achieve Salvation and Shows Proof in New Letter 2Health News:UV Technologies, LLC Developing New More Effective UV-Aid for Flu and Cold Prevention 2
... LifeCare Holdings, Inc. (the,"Company") today announced its operating results ... Our net patient service revenue increased by $6.4 million, ... $88.8 million from $82.4 million,for the comparable period in 2007. ... than the same period in 2007., The increase in ...
... Patient safety in hospitals focus of 48 NQF-endorsed ... patient,safety remains a major hurdle in the United ... voluntary consensus standards focused on,measuring the performance of ... readmission, and prevention and care,of venous thromboembolism., ...
... - QLT Inc. (NASDAQ: QLTI; TSX:,QLT) announced today that ... the land and building comprising its corporate headquarters and ... with the closing of the transaction, QLT will enter ... continue its operations., "We are very pleased that ...
... appear to help quality of life for lung cancer ... -- Adding chemotherapy to other treatments being giving to ... asbestos exposure, does not appear to improve either survival ... which is usually fatal, is a cancer of the ...
... Corporation,("Select") today announced results for its first quarter ... ended March 31, 2008, net operating revenues,increased 17.4% ... the same,quarter, prior year. Income from operations decreased ... the same quarter, prior year. Net income,decreased 47.9% ...
... Governor Paterson,s leadership in proposing prescription,drug marketing reform ... AARP strongly believes,New York has a paramount interest ... address the undue influence that,pharmaceutical companies have over ... but the treatment they receive., The reforms ...
Cached Medicine News:Health News:LifeCare Holdings, Inc. Announces First Quarter Results 2Health News:LifeCare Holdings, Inc. Announces First Quarter Results 3Health News:LifeCare Holdings, Inc. Announces First Quarter Results 4Health News:LifeCare Holdings, Inc. Announces First Quarter Results 5Health News:LifeCare Holdings, Inc. Announces First Quarter Results 6Health News:LifeCare Holdings, Inc. Announces First Quarter Results 7Health News:LifeCare Holdings, Inc. Announces First Quarter Results 8Health News:LifeCare Holdings, Inc. Announces First Quarter Results 9Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:QLT Inc. announces agreement for sale of real estate 2Health News:QLT Inc. announces agreement for sale of real estate 3Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 2Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 3Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 4Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 5Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 6Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 7Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 8Health News:Select Medical Corporation Announces Results for First Quarter Ended March 31, 2008 9Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
... mounts on a standard ring stand rod ... 1/2" ) mounting rod. The 14cm (5 ... the source of fumes. A top connector ... to an aspirator or vacuum source. Tubing, ...
... These corrosion proof polypropylene exhaust hoods are ... of tanks and draw a stream of ... away from the operator. Other sizes and ... lateral, and double-slot are available on special ...
... The Benchtop Fume Hood is an ... installations in which a number of fume ... schools, junior colleges and universities. Features include ... polyethylene with rounded inside corners for easy ...
Medicine Products: